NACL Industries Ltd
NACL is an established player and they deal in both technicals and formulations and they cater to the Indian market and to the international market as well. They have over 50 products covering all major crops. They have a strong logistic presence and the products are sold in more than 55,000 counters. NACL has become one of the reliable contract manufacturers for major MNCs. NACL exports products to over 30 countries and has forayed into International Brand business by registering brands in South-East Asia and Africa and are in the process of expanding reach in these regions. [1] [2]
- Market Cap ₹ 1,159 Cr.
- Current Price ₹ 57.8
- High / Low ₹ 85.0 / 48.6
- Stock P/E
- Book Value ₹ 25.4
- Dividend Yield 0.00 %
- ROCE -0.04 %
- ROE -10.8 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of 7.21% over last 3 years.
- Company has high debtors of 157 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Agro Chemicals Industry: Pesticides / Agrochemicals - Indian
Part of BSE Commodities BSE Allcap BSE SmallCap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
601 | 636 | 746 | 692 | 735 | 847 | 865 | 1,015 | 1,191 | 1,633 | 2,116 | 1,779 | 1,588 | |
583 | 625 | 701 | 636 | 679 | 798 | 852 | 946 | 1,078 | 1,495 | 1,922 | 1,762 | 1,536 | |
Operating Profit | 18 | 11 | 44 | 56 | 56 | 49 | 14 | 69 | 113 | 138 | 193 | 17 | 51 |
OPM % | 3% | 2% | 6% | 8% | 8% | 6% | 2% | 7% | 10% | 8% | 9% | 1% | 3% |
18 | 16 | 26 | 18 | 41 | 20 | 27 | 8 | 15 | 13 | 10 | 10 | 12 | |
Interest | 31 | 28 | 35 | 37 | 38 | 33 | 34 | 29 | 28 | 27 | 47 | 76 | 74 |
Depreciation | 25 | 22 | 25 | 27 | 28 | 20 | 20 | 24 | 25 | 25 | 28 | 27 | 28 |
Profit before tax | -20 | -23 | 10 | 11 | 31 | 15 | -13 | 24 | 75 | 100 | 128 | -76 | -38 |
Tax % | -36% | -9% | 27% | 18% | -4% | 25% | -48% | 30% | 32% | 26% | 26% | -23% | |
-13 | -21 | 8 | 10 | 33 | 12 | -7 | 17 | 51 | 73 | 95 | -59 | -31 | |
EPS in Rs | -0.70 | -1.32 | 0.54 | 0.62 | 2.09 | 0.74 | -0.42 | 0.87 | 2.60 | 3.70 | 4.77 | -2.96 | -1.54 |
Dividend Payout % | 0% | 0% | 19% | 16% | 6% | 17% | 0% | 12% | 15% | 15% | 15% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 11% |
5 Years: | 16% |
3 Years: | 14% |
TTM: | -22% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -292% |
Stock Price CAGR | |
---|---|
10 Years: | 17% |
5 Years: | 18% |
3 Years: | -11% |
1 Year: | -20% |
Return on Equity | |
---|---|
10 Years: | 7% |
5 Years: | 8% |
3 Years: | 7% |
Last Year: | -11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 15 | 16 | 16 | 16 | 16 | 16 | 17 | 19 | 20 | 20 | 20 | 20 | 20 |
Reserves | 180 | 159 | 162 | 170 | 213 | 223 | 267 | 338 | 399 | 469 | 554 | 491 | 486 |
177 | 219 | 228 | 232 | 213 | 237 | 210 | 268 | 202 | 531 | 724 | 789 | 522 | |
228 | 227 | 260 | 193 | 209 | 237 | 248 | 330 | 355 | 496 | 616 | 518 | 617 | |
Total Liabilities | 600 | 621 | 665 | 611 | 651 | 713 | 742 | 955 | 976 | 1,516 | 1,914 | 1,818 | 1,645 |
172 | 182 | 176 | 167 | 163 | 158 | 141 | 191 | 220 | 238 | 402 | 439 | 457 | |
CWIP | 11 | 18 | 12 | 6 | 7 | 5 | 21 | 42 | 36 | 116 | 71 | 47 | 29 |
Investments | 4 | 9 | 12 | 13 | 9 | 9 | 14 | 15 | 16 | 13 | 14 | 15 | 15 |
413 | 411 | 466 | 426 | 473 | 541 | 566 | 707 | 704 | 1,148 | 1,427 | 1,318 | 1,144 | |
Total Assets | 600 | 621 | 665 | 611 | 651 | 713 | 742 | 955 | 976 | 1,516 | 1,914 | 1,818 | 1,645 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
76 | 31 | 40 | 46 | 58 | 24 | 36 | 103 | 83 | -124 | -20 | 50 | |
-5 | -47 | -18 | -12 | -6 | -14 | -27 | -97 | 14 | -163 | -143 | -38 | |
-74 | 11 | -27 | -33 | -58 | -11 | -9 | 70 | -113 | 290 | 134 | -22 | |
Net Cash Flow | -3 | -5 | -4 | 1 | -5 | -1 | 0 | 77 | -16 | 2 | -28 | -9 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 100 | 92 | 108 | 99 | 110 | 124 | 113 | 129 | 103 | 118 | 133 | 157 |
Inventory Days | 154 | 140 | 138 | 153 | 189 | 141 | 134 | 84 | 100 | 124 | 112 | 92 |
Days Payable | 113 | 97 | 121 | 89 | 127 | 127 | 125 | 137 | 120 | 112 | 110 | 87 |
Cash Conversion Cycle | 141 | 135 | 125 | 163 | 172 | 137 | 122 | 76 | 83 | 129 | 135 | 162 |
Working Capital Days | 97 | 93 | 90 | 119 | 126 | 124 | 125 | 90 | 89 | 123 | 128 | 148 |
ROCE % | 3% | 2% | 11% | 12% | 10% | 11% | 4% | 10% | 17% | 15% | 15% | -0% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
13h - Appointment of new CFO and President, transition of current CFO.
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
14h - NACL Industries Limited has informed about the allotment of 55,00 shares
-
NACL Industries Limited Has informed Regarding Forfeiture And Granting Of Options
14h - Approval of stock options and allotment of shares.
-
Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI (LODR) Regulations, 2015
19h - Approval for issuance of warrants and equity shares.
-
Board Meeting Intimation for Board Intimation For Raising Of Funds Through Issue Of Securities On Preferential Basis
9 Dec - Board meeting to discuss fund raising proposals.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Feb 2024TranscriptNotesPPT
-
Jan 2024TranscriptNotesPPT
-
Sep 2023TranscriptNotesPPT
-
Jun 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Jan 2022TranscriptNotesPPT
-
Jan 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Aug 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Mar 2021TranscriptNotesPPT
-
Dec 2020TranscriptNotesPPT
Products[1]
Key technicals:
Insecticides: Cairo, Fenny, Nagarjuna 4G, PestLock, etc.
Herbicides: Font, Slogan, Nagarjuna Combi plus, etc.
Fungicides: Combi plus, Kazan, Result, Subtle Plant Growth Regulators :Atonik, Gallant EG, Gallant Gold
Company has 63 branded products.[2]